CUAMC
KLRS

China Universal Asset Management Company’s Kalaris Therapeutics KLRS Stock Holding History

China Universal Asset Management Company’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-127
Closed -$6.27K – 485
2023
Q3 		$6.27K Buy
127
+74
+140% +$5.04K ﹤0.01% 377
2023
Q2 		$4.17K Sell
53
-2
-4% -$190 ﹤0.01% 385
2023
Q1 		$4.99K Buy
55
+14
+34% +$1.78K ﹤0.01% 367
2022
Q4 		$4.86K Buy
41
+3
+8% +$509 ﹤0.01% 302
2022
Q3 		$7K Buy
+38
New +$5.92K ﹤0.01% 240

Other funds holding KLRS

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return

China Universal Asset Management Company's KLRS Position: Q4 2023 in Review

China Universal Asset Management Company sold out of Kalaris Therapeutics (KLRS) in Q4 2023, closing a stake of 127 shares — an estimated $6.27K sold.

China Universal Asset Management Company first reported a position in KLRS in Q3 2022 and held it in 5 quarters. The position peaked at $7K in Q3 2022. 81 funds tracked by Wall St. Rank hold KLRS as of Q4 2023.

  • China Universal Asset Management Company reported no remaining Kalaris Therapeutics position as of Q4 2023 after selling out during the quarter.
  • China Universal Asset Management Company sold 127 Kalaris Therapeutics shares in Q4 2023, an estimated $6.27K.
  • China Universal Asset Management Company first reported a position in Kalaris Therapeutics in Q3 2022 and held it in 5 quarters.
  • China Universal Asset Management Company's Kalaris Therapeutics position peaked at $7K in Q3 2022.
  • 81 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2023.

Based on China Universal Asset Management Company's 13F filing for Q4 2023, filed 24 Jan 2024.